Top

Published in:

01-12-2007

Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients

Authors: Adriano de Paula Sabino, Daniela Amorim Melgaço Guimarães, Daniel Dias Ribeiro, Sabrina Guimarães Paiva, Luci Maria Sant’Ana Dusse, Maria das Graças Carvalho, Ana Paula Fernandes

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2007

Abstract

Introduction

Of the inherited thrombophilias, the Factor V Leiden (FVL) and the prothrombin mutant (FII G20210A) are associated with increased risk of venous thromboembolism (VTE). The C677T mutation of the methylenetetrahydrofolate reductase gene, which may lead to hyperhomocysteinemia, is also considered a risk factor for VTE in some studies. However, the frequency of these genetic risk factors may vary significantly among different populations.

Material and methods

The FVL, FII G20210A and C677T mutations were investigated by PCR-RFLP in 275 young VTE Brazilian patients as well as in 324 biologically unrelated individuals selected to compose the control group.

Results

The C677T mutation in the MTHFR gene was detected in 135 (49.1%) patients, of which 117 (42.5%) were identified as heterozygous and 18 (6.5%) as homozygous. The G20210A mutation was detected in 14 (5.1%) patients in heterozygosis. In both cases, no significant difference was observed when these results were compared to the frequencies observed in the control group. FVL was detected in heterozygosis in 19 (6.9%) patients, corresponding to a significantly increased frequency when compared to that observed for the control group (1.2%) (OR 5.9; 95% CI 2.08–16.79; p < 0.001).

Conclusions

The data indicated that FVL is significantly associated with VTE among young Brazilian patients, but also supported previous evidence that VTE is a multi-factorial disease, resulting from the interaction of genetic and acquired risk factors.

Collins R, Scrimgeour A, Yusuf S et al (1988) Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318:1162–1173PubMedCrossRef

Clarke-Pearson DL, DeLong ER, Synan IS et al (1987) Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. Obstet Gynecol 69:146–150PubMed

Samama MM (1993) Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice: the SIRIUS study. Thromb Haemost 69:763

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596PubMedCrossRef

Rosendaal FR (1999) Venous thrombosis: prevalence and interaction of risk factors. Haemostasis Suppl S1:1–9CrossRef

Dahlbaeck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90:1004–1008CrossRef

Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503–1506PubMedCrossRef

Bertina RM, Koeleman BPC, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67PubMedCrossRef

Poort SW, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed

10.

Frosst P, Blom HJ, Milos R et al (1995) A candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113PubMedCrossRef

11.

Undas A, Domagala B, Jankowski M, Szczeklik A (1999) Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. Thromb Res 95:281–288PubMedCrossRef

12.

Franco RF, Santos SEB, Elion J, Tavella MH, Zago MA (1998) The prevalence of the G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in different human populations. Acta Haematol 100:9–12PubMedCrossRef

13.

Rosendaal FR, Doggen CJ, Zivelin A et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706–708PubMed

14.

Rodrigues CA, Rocha LKA, Morelli VM, Franco RF, Lourenço DM (2004) Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost 2:1211–1212PubMedCrossRef

15.

Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ (2003) Color and genomic ancestry in Brazilians. PNAS 100:177–182PubMedCrossRef

16.

Huber S, Mcmaster KJ, Voelkerding KV (2000) Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A. J Mol Diagn 2:153–157PubMed

17.

Dean AG, Dean JA (1997) Coulombier, D. Epi Info, version 6.04: a word processing database and statistics program for epidemiology on microcomputers. Centre of Disease Control and Prevention, Atlanta

18.

Rosendaal FR, Sicovick DS, Schwartz SM et al (1999) Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89:2817–2821

19.

Salomon O, Steinberg DM, Zivelin A et al (1999) Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 19: 511–518PubMed

20.

Simioni P, Tormene D, Prandoni P et al (2002) Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 99:1938–1942PubMedCrossRef

21.

Sabino AP, Ribeiro DD, Carvalho MG, Cardoso J, Dusse LMS, Fernandes AP (2006) Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 17:271–275CrossRef

22.

Voetsch B, Damasceno BP, Camargo EC et al (2000) Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 83:229–233PubMed

23.

Eichinger S, Pabinger I, Stumpflen A et al (1997) The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 77:624–628PubMed

24.

Eichinger S, Weltermann A, Mannhalter C et al (2002) The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 162(20):2357–2360PubMedCrossRef

25.

De Stefano V, Martinelli I, Mannucci PM et al (1999) The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341:801–806PubMedCrossRef

26.

den Heijer M, Willems HP, Blom HJ (2007) Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109:139–144CrossRef

27.

Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L (1999) The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 93:1–8PubMedCrossRef

28.

De Stefano V, Rossi E, Paciaroni K et al (2003) Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene. Haematologica 8:61–66

29.

Bernstein D, Coupey S, Schonberg SK (1986) Pulmonary embolism in adolescents. Am J Dis Child 140:667–671PubMed

30.

Wu O, Robertson L, Langhorne P et al (2005) Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 94:17–25PubMed

31.

Mohllajee AP, Curtis KM, Martins SL, Peterson HB (2006) Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 73:166–178PubMedCrossRef

32.

Rosendaal FR, Helmerhorst FM, Vandenbroucke JP (2001) Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 86:12–23

33.

Rosendaal FR, Helmerhorst FM, Vandenbroucke JP (2002) Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22:201–210PubMedCrossRef

Title: Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients
Authors: Adriano de Paula Sabino
Daniela Amorim Melgaço Guimarães
Daniel Dias Ribeiro
Sabrina Guimarães Paiva
Luci Maria Sant’Ana Dusse
Maria das Graças Carvalho
Ana Paula Fernandes
Publication date: 01-12-2007
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2007
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-007-0024-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Material and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2007

Inhibition of collagen, and thrombin-induced platelet aggregation by Lansberg’s hognose pit viper (Porthidium lansbergii hutmanni) venom

Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervension in patients with coronary artery disease

G20210A Prothrombin gene variant in Turkish patients with angiographically documented coronary artery disease

Unusual case of aortic valve involvement in patient with Löffler’s Endomyocarditis: management, follow-up and short review of the literature

sICAM-1 measurements are independent of processing method and sampling site in patients with coronary artery disease

Drug eluting stents for ST-elevation myocardial infarction: risk and benefit

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials